CUMBERLAND PHARMACEUTICALS INC 8-K/A filed 2026-09-11

Cumberland Pharmaceuticals Inc filed this 8-K/A on 2026-09-11. It amends an earlier report under Item 5.07, Submission of Matters to a Vote of Security Holders, covering the company's Annual Meeting of Shareholders held on April 21, 2026. The filing was signed by John Hamm, Chief Financial Officer, and is dated September 11, 2026. The amendment concerns one proposal from that meeting: an advisory vote on how often shareholders should cast future advisory votes on the compensation of the company's named executive officers. The filing states that, as originally reported, the frequency of every three years received the highest number of shareholder votes. After further discussion, the Board of Directors has determined that advisory votes on named executive officer compensation will be held every three years, until the next required advisory vote on frequency. The filing also states that the company is required to hold the frequency vote every six years. For an analyst or journalist tracking governance, this sets the schedule for shareholder input on executive pay at Cumberland: the Board has chosen a three-year cycle, in line with the option that drew the most votes. The vote tallies for each frequency option are not in the filing excerpt. The date of the original report is also not in the filing. So are the other matters voted on at the 2026 Annual Meeting, which the excerpt mentions only as "among other matters." The full document is available at the source link for readers who want the complete record.